Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $1.6 million.

  • Sutro Biopharma's Share-based Compensation fell 7628.72% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year decrease of 2691.34%. This contributed to the annual value of $24.7 million for FY2024, which is 88.73% down from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Share-based Compensation is $1.6 million, which was down 7628.72% from $5.3 million recorded in Q2 2025.
  • Sutro Biopharma's Share-based Compensation's 5-year high stood at $7.0 million during Q1 2022, with a 5-year trough of $1.6 million in Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $6.1 million (2024), whereas its average is $5.9 million.
  • In the last 5 years, Sutro Biopharma's Share-based Compensation skyrocketed by 12309.69% in 2021 and then plummeted by 7628.72% in 2025.
  • Over the past 5 years, Sutro Biopharma's Share-based Compensation (Quarter) stood at $6.9 million in 2021, then dropped by 15.03% to $5.9 million in 2022, then rose by 6.34% to $6.2 million in 2023, then fell by 4.95% to $5.9 million in 2024, then crashed by 73.76% to $1.6 million in 2025.
  • Its Share-based Compensation was $1.6 million in Q3 2025, compared to $5.3 million in Q2 2025 and $5.5 million in Q1 2025.